SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Intercept Pharmaceuticals, Inc. (ICPT) 当前追踪市盈率 (P/E) 为 5.6. 追踪盈利收益率为 17.89%.
本页证实的标准:
- VALUE (86/100, 通过) — 市盈率低于市场平均水平 (5.6); 分析师目标价暗示上行空间 (+16.4%); 盈利收益率超过债券收益率 (17.89%).
- 追踪盈利收益率 17.89% — 超过典型债券收益率（约4.3%），使股票相对固定收益更具吸引力。
- 分析师共识目标价 $22.11 (+16.4% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 62/100 其中 3/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
86/100
Price-to-Earnings & upside
Proven by this page
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概览 — ICPT
估值倍数
P/E (TTM)5.6
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率2.25
EV/EBITDA0.0
每股数据
EPS (TTM)$3.40
每股账面价值$0.00
每股营收$8.44
每股自由现金流$0.00
收益率与内在价值
盈利收益率17.89%
股息收益率0.00%
分析师目标价$22.11 (+16.4%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2013 |
$-3.76 |
$1.62M |
$-67.79M |
-4180.5% |
| 2014 |
$-13.63 |
$1.74M |
$-283.23M |
-16258.7% |
| 2015 |
$-9.56 |
$2.78M |
$-226.43M |
-8139.1% |
| 2016 |
$-16.74 |
$24.95M |
$-412.83M |
-1654.6% |
| 2017 |
$-14.38 |
$130.96M |
$-360.37M |
-275.2% |
| 2018 |
$-10.86 |
$179.8M |
$-309.24M |
-172% |
| 2019 |
$-12.35 |
$252M |
$-391.05M |
-155.2% |
| 2020 |
$-9.83 |
$312.69M |
$-324.23M |
-103.7% |
| 2021 |
$-4.55 |
$363.47M |
$-145.02M |
-39.9% |
| 2022 |
$3.40 |
$285.71M |
$115.17M |
40.3% |
